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Background: Total knee arthroplasty (TKA) is often associated with a severe local inflammatory reaction which,
unless controlled, leads to persistent pain up to one year after surgery. Standard and accelerated rehabilitation
protocols are currently being implemented after TKA, but no consensus exists regarding the long-term effects.
Biophysical stimulation with pulsed electromagnetic fields (PEMFs) has been demonstrated to exert an
anti-inflammatory effect, to promote early functional recovery and to maintain a positive long-term effect in
patients undergoing joint arthroscopy. The aim of this study was to evaluate whether PEMFs can be used to limit
the pain and enhance patient recovery after TKA.
Methods: A prospective, randomized, controlled study in 30 patients undergoing TKA was conducted. Patients
were randomized into experimental PEMFs or a control group. Patients in the experimental group were instructed
to use I-ONE stimulator 4hours/day for 60days. Postoperatively, all patients received the same rehabilitation
program. Treatment outcome was assessed using the Knee Society Score, SF-36 Health-Survey and VAS. Patients
were evaluated pre-operatively and one, two, six and 12 months after TKA. Joint swelling and Non Steroidal Anti
Inflammatory Drug (NSAID) consumption were recorded. Comparisons between the two groups were carried out
using a two-tail heteroschedastic Student’s t-test. Analysis of variance for each individual subject during the study
was performed using ANOVA for multiple comparisons, applied on each group, and a Dunnet post hoc test. A p
value< 0.05 was considered statistically significant.
Results: Pre-operatively, no differences were observed between groups in terms of age, sex, weight, height,
Knee-Score, VAS, SF-36 and joint swelling, with the exception of the Functional Score. The Knee-Score, SF-36 and
VAS demonstrated significantly positive outcomes in the I-ONE stimulated group compared with the controls at
follow-ups. In the I-ONE group, NSAID use was reduced and joint swelling resolution was more rapid than in
controls. The effect of I-ONE therapy was maintained after use of the device was discontinued.
Conclusions: The results of the study show early functional recovery in the I-ONE group. I-ONE therapy should be
considered after TKA to prevent the inflammatory reaction elicited by surgery, for pain relief and to speed
functional recovery.
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Osteoarthritis (OA) is a degenerative joint disease that
affects approximately 10% of adults over the age of 50
[1]. Patients report a progressive increase in pain leading
to functional limitations and impaired mobility. OA is
the main indication for Total Knee Arthroplasty (TKA).
Each year, over 40,000 TKA procedures are performed
in Italy [2]. Satisfactory clinical outcome of TKA can de-
pend on several factors including the type of implant
and surgical procedure; however, after TKA, local joint
swelling, inflammation and pain can delay patient recov-
ery or limit joint function in the long term, and that
may ultimately lead to altered posture and reduced mo-
bility [3,4]. A recent study demonstrated that patient
post-operative functional recovery after TKA is inversely
correlated to the intra-articular concentration of the
pro-inflammatory cytokine IL-6, emphasizing the re-
quirement to control the inflammatory reaction of the
joint to surgery [5]. In an attempt to favor patient func-
tional recovery after TKA, detailed rehabilitation proto-
cols have been developed including exercise instructions
and physiotherapy.
Oral Non Steroidal Anti Inflammatory Drugs (NSAIDs)
are used to control pain and inflammation in the operated
knee. However, their use for periods exceeding 72 hours in
an aged population must take into account the possible
negative side effects, such as reduction in renal perfusion
and gastric mucosa damage.
Recent studies have indicated that the physiological
pathway leading to resolution of inflammatory processes
can be mediated by the activation of adenosine recep-
tors, with the A2A adenosine receptors demonstrating
the highest anti-inflammatory activity [6,7]. It has been
demonstrated that Pulsed ElectroMagnetic Fields
(PEMFs) have an agonist activity for the A2A adenosine
receptor in neutrophils, chondrocytes and synoviocytes,
and this explains the anti-inflammatory effect of PEMFs
observed in the knee joint [8,9]. Level I clinical trials
conducted in patients undergoing knee joint surgery
have demonstrated that PEMF treatment reduces joint
swelling, the requirement of NSAIDs to control pain,
and the time to functional recovery, and it is well
accepted by patients [10,11].
The aim of this study was to test whether treatment
with PEMFs, as an adjuvant to standard rehabilitation,
could limit pain and joint swelling immediately after
TKA and shorten the time to functional recovery.
Methods
Patients and design of study
In the period between 2008 and 2010, at the Orthopedic
and Traumatology Operative Unit of University of Bari
in Italy, a prospective, randomized, controlled study was
performed to test whether treatment with PEMFs couldfavor functional recovery in patients undergoing TKA.
The study was designed without placebo devices, follow-
ing Local Ethical Committee indications that did not
consider appropriate to ask patients to devote four hours
per day for 60 days to using a placebo device, knowing
the anti-inflammatory activity of the treatment. The
study was approved by the Local Ethical Committee, and
patients signed informed consent for recruitment.
The inclusion criteria were the following: patients aged
between 60 and 85 years, presenting with an advanced
state of knee OA and scheduled for TKA, with varus or
valgus deformity not exceeding 20° or 15°, respectively,
and with a flexion contracture of less than 15°. Exclusion
criteria were: previous surgery to the same knee, omo-
lateral hip prosthesis, Body Mass Index (BMI; Kg/m2)
>30, rheumatoid arthritis, autoimmune diseases, sys-
temic diseases, cancer and the use of steroids.
Biophysical stimulation
Thirty patients were randomly assigned to the experi-
mental and control groups. At selection, the clinician
informed the patient regarding the chance to be
recruited in a trial with two arms. At enrollment, the pa-
tient accepted to be addressed to one of the two groups
for the entire duration of the study and the patient
signed informed consent for recruitment. The assign-
ment of the patient to experimental or control group
was performed using a web-based computer program
(www.randomization.com) built on the randomization
criteria: sex (M/F), age (60-75 years; 75-85 years) and
smoking status (yes/no).
Patients in the experimental group were instructed to
use PEMFs (I-ONE therapy) four hours per day for 60
days by an independent, unblinded research assistant,
who will not be involved in patient care or assessment.
Physicians, as well as medical assessors, were blinded to
the allocation of patients in the study groups.
All devices were provided by the manufacturer at no
cost. Treatment began within seven days from TKA, and
continued at the rehabilitation centre or at the patient’s
home. The battery-operated device (I-ONE, IGEA,
Carpi, Italy) generated a peak magnetic field of 1.5 mT
at a frequency of 75 Hz (Figure 1); the coil was placed
on the operated knee, but not in direct contact with the
skin. The apparatus had a timer to record the hours of
therapy, allowing patient compliance to be monitored.
Patients were instructed to interrupt the treatment if
there were adverse events such as a burning sensation or
skin irritation. Both groups underwent the same re-
habilitation protocol.
Surgical procedure
For all patients, TKA was performed by the same surgeon
and the same anesthesiologist. Anesthesia was obtained
Figure 1 I-ONE therapy. Left: waveform of magnetic field 1.5 mT peak value (top); waveform of induced electrical field 0.051 mV/cm peak value,
as detected using a standard coil probe (50 turns, 0.5 cm internal diameter of the coil probe, 0.2 mm copper diameter) (bottom). Right: I-ONE
PEMF generator.
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the space L3-L4 or L4-L5 with 25 GA needles of 2 ml of
levobupivacaine at 0.5%. The post-operative pain was trea-
ted with continuous venous infusion of tramadol and
ketorolac using an elastomeric pump for 48 hours. Using
a femoral perineural catheter, 20 ml of levobupivacaine at
0.2% were administered daily, one hour prior to rehabilita-
tion, until the fifth day after surgery. For all patients, from
day five until discharge, 1 g of oral paracetamol was admi-
nistered as required. Cemented Genesis 2 CR total pros-
thesis (Genesis 2CR, Smith and Nephew, 3175 Coughlin
Drive, Memphis, TN 38116, USA) was implanted follow-
ing a standard procedure.
Rehabilitation
Kinesitherapy began on the same day of surgery, with
passive mobilization on Kinetec (Kinetec RIMEC Fisio-
tec 2000, Loc Broine 57/a, Roveggio, Bo, Italy) from 60°
to 90° bending for 90 minutes. On subsequent days, this
was continued with bending from 0° to 90° for 90 min
per day using the Kinetec in the afternoon; from day
three, patients began cautious passive and active assisted
mobilization of hip, knee and ankle, exercises for muscu-
lar reinforcement of lower limbs, assisted walking with
two crutches and partial weight bearing on the operated
limb and isometric exercises for the lower limbs.
Clinical assessment
Patients were required to complete subjective assessment
forms and the physician to complete the objective ones.
Assessments were performed pre-operatively and at one,
two, six and 12 months post-operatively and included:
– the Visual Analogue Scale (VAS), a 10 cm horizontal
line, where the left end represents no pain, and the
right end maximum possible pain or unbearable pain;– The Knee Society Score including: (a) Knee Score
to assess pain, range of motion, stability,
contracture in bending, active extension deficit and
alignment); (b) Functional Score to evaluate
autonomy in walking, stair climbing, use of a stick
or frame. Both score values ranged from 0 to 100
[12].
– SF-36 Health Survey that required the patient to
answer 36 questions [13]. The mean value of the
resulting eight quantitative dimensions was
calculated and reported as the final SF-36 score.
– Joint swelling score: knee girth was determined by
measuring the transverse plane circumference of
both knees at midpatellar height in the supine
position, using a flexible plastic measuring tape;
girth difference in cm between limbs is related to
functional outcome after TKA [14]. No girth
difference between knees scores 40 (mild), less than
0.5 cm 30 (moderate), between 0.5 and 1 cm 20
(tense), between 1 and 1.5 cm 10 (severe) and more
than 1 cm 0 (high).
– Patients were asked if they used NSAIDs at each
follow-up visit.
Statistical method
The sample size was calculated on the primary out-
come of the study, i.e. the pain, expressed as VAS,
given the presence in the literature of several studies
concerning the effects of electromagnetic fields on
pain [10,11,15].
Starting from two groups that were homogeneous as
regards the mean value of VAS at baseline, was
hypothesized a difference in the mean VAS value of
two units between the two groups from the first
month of therapy, with a standard deviation of two
units. In the power analysis used to calculate the
Table 1 Baseline patient characteristics
Control group (#15) I-ONE group (#15) p
valueAverage, St.Dev Average St.Dev
Age (years) 70.5 8.1 70.0 10.6 0.894
Weight (kg) 73.4 13.3 77.6 16.1 0.464
Height (cm) 163.0 7.9 164.9 7.4 0.502
Knee Score 42.1 13.9 39.5 13.8 0.620
Functional Score 21.0 18.8 39.3 25.1 0.032
SF-36 Health
Survey Score
28.6 8.1 36.7 13.7 0.060
VAS 7.6 1.8 6.5 2.0 0.107
Joint Swelling Score 18.0 12.6 19.3 10.3 0.754
Characteristics of the groups at baseline: control group and I-ONE therapy
group.
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Where n is the minimum number of patients per group,
z2α ¼ 1:96 for a two tailed significance of p = 0.05, z2β ¼
0:842 for a power of 80%, σ is the standard deviation and
δ is the hypothesized difference between groups.
From this, given our assumptions, the minimum num-
ber of subjects per group is 15.
The normality distribution of the two samples was
tested using the Kolmogorov-Smirnov test and all quan-
titative variables appeared to be normally distributed.
The descriptive analysis of the continuous variables was
performed by calculating the mean value and the stand-
ard deviation in each group. The two groups were com-
pared at baseline and at all follow-ups by calculating the
mean value of the parameters of study and the mean
value of the their variations with respect to the baseline.
The statistical model employed for comparison of the
two groups was the two-tailed heteroschedastic Student’s
t-test, whilst for analyses among follow-up and baseline
values on each group ANOVA test for multiple compari-
sons and post hoc Dunnet test was performed.
Contingency tables were used to test differences in
categorical variables between the two groups at baseline
and at each follow-up visit using the chi square test with
Yate’s correction, whilst for analyses on the time effect
on each group, non parametric tests for multiple related
samples were used with Friedman test.
The statistician was blind regarding the treatment and
control group. The statistical analyses were conducted
using the Statistical Packages for Social Sciences (SPSS
Inc. Chicago, ILL, US).
Results
At the baseline, no statistically significant differences were
observed between the two groups with the exception of
the Functional Score, Table 1. Patient compliance was sat-
isfactory, and the average daily use of I-ONE was 3.9 ± 0.5
hours. No side effects were recorded and no patient dis-
continued the treatment.
Knee score
In both groups, follow-up Knee scores were greater than
the pre-operative baseline values, and the changes were
statistically significant at two, six and 12 months
(p< 0.05) in the experimental group, but only at six and
12 months in the control group (p< 0.05). Intergroup
analysis demonstrated that the Knee score in the I-ONE
group was significantly higher after two months (72.1± 15.3
vs. 45.7 ± 17.1; p< 0.0001) and six months (74.4 ± 14.5vs. 52.1 ± 15.3; p< 0.0001) than in controls. At 12
months, no difference was observed between groups
(p = 0.097), (Figure 2).
Functional score
The Functional Score increased with respect to baseline
and was significant at two months follow-up (p< 0.05) in
the experimental group, whilst in the control group the in-
crease became significant at six months. There was no
statistically significant difference between the two groups
one month after surgery (p= 0.124), but there were highly
significant differences between the groups at two months
(66.0 ± 28.7 vs. 40.4± 17.5, p< 0.0001), six months
(80.0 ± 19.4 vs. 51.0 ± 18.2, p< 0.0001) and 12 months
(87.3 ± 16.8 vs. 55.0± 33.2, p< 0.005) (Figure 3A).
The baseline values of Functional Score in the I-ONE
group were significantly higher than those of the control
group. Therefore, a further analysis was conducted, tak-
ing into account the changes recorded at follow-up visits
versus the baseline. This analysis did not demonstrate
significant differences between groups at follow-ups;
however, at six and 12 months, the experimental group
values were higher than controls (Figure 3B).
SF36 health survey
One month after TKA the SF-36 Health Survey score in
the I-ONE group was significantly higher than the control
group (60.5 ± 14.4 vs. 29.5± 10.5, p< 0.0001) and the
baseline (p< 0.05). The difference between groups was
maintained at all follow-up visits: two months (65.8 ± 15.2
vs. 32.5± 9.2, p< 0.0001), six months (75.1 ± 9.6 vs.
49.5± 17.2, p< 0.0001) and 12 months (76.3 ± 8.7 vs.
59.7± 19.6, p< 0.05) (Figure 4).
VAS
The pre-operative pain values of both groups were high
(I-ONE group 6.5± 2.0 vs. control 7.6± 1.8, p=0.107).
Figure 5 demonstrates the decline in VAS values during
Figure 2 Knee Score. Mean values of Knee Score in the control group and I-ONE therapy group during the study. Vertical bars represent the
standard error. *p< 0.0001, p values refer to a comparison between groups at each follow-up visit by two tailed heteroschedastic Student’s t-test.
+p< 0.05, statistically significant difference versus pre-op.
Figure 3 Functional Score. (A) Mean values of Functional Score in the control group and I-ONE therapy group during the study. Vertical bars
represent the standard error. *p< 0.0001, ^p< 0.005, }p< 0.05, p values refer to a comparison between groups at each follow-up visit by two
tailed heteroschedastic Student’s t-test. +p< 0.05, statistically significant difference versus pre-op. (B) Mean changes in Functional Score in control
and I-ONE groups during the follow-up compared with baseline values. Vertical bars represent standard errors.
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Figure 4 SF-36 Health Survey Score. Mean values of SF-36 Health Survey in the control group and I-ONE therapy group during the study.
Vertical bars represent the standard error. *p< 0.0001, }p< 0.05, p values refer to a comparison between groups at each follow-up visit using two
tailed heteroschedastic Student’s t-test. +p< 0.05, statistically significant difference versus pre-op.
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shows significantly lower values than baseline in both
groups (p< 0.05). VAS values were significantly lower in
the experimental than the control group at all follow-up vis-
its: one month (2.4±1.6 vs. 4.9±1.8, p< 0.0001), two
months (1.1±1.0 vs. 4.6±1.8, p< 0.0001), six months
(1.5±2.8 vs. 5.6±2.9, p< 0.001) and 12 months (0.5±1.3
vs. 3.6±3.9, p< 0.05).
Swelling
Swelling was resolved in both groups and was significantly
reduced at the follow-up visits with respect to baseline
(p< 0.05). The percentage of subjects with mild to moder-
ate swelling was significantly higher in the I-ONE group
with respect to control group at 1 and 2 months after
surgery (p< 0.05 and p< 0.0001, respectively). No differ-
ence between groups was observed at 6 and 12 months
(Table 2).
Use of NSAIDs
One month after TKA, 33% of patients in the I-ONE
group used NSAIDs as compared with 93% in the con-
trol group (RR= 8.11 C.I. 1.23-53.57, p = 0.0017). At twoTable 2 Joint swelling
Control group I-ONE group p value
Pre-op 27 20 ns
1 month 67 100 <0.05
2 months 33 100 <0.0001
6 months 87 100 ns
12 months 87 100 ns
Percentage of patients with mild to moderate swelling in control and I-ONE
treated groups at each study visit. p values refer to a comparison between
groups at each follow-up visit using chi square test with Yate’s correction.and six months, the percentages of patients using
NSAIDs in the experimental and control group were 7%
and 86% (RR = 7.39 C.I. 2-27.26, p< 0.0001), and 7% and
46% (RR = 2.57 C.I. 1.31-5.06, p< 0.05), respectively. At
12 months, no difference was observed between groups.
Discussion
TKA is the most common and effective surgical procedure
for the treatment of OA, leading to satisfactory functional
recovery in patients. However, it can be associated with
moderate or severe post-operative pain and an intense
inflammatory reaction. Pain stems from the onset of
loco-regional inflammation, and the presence of pro-
inflammatory cytokines (interleukin-1beta: IL-1β, IL-6),
tumor necrosis factor-α, histamine, bradykinin, prosta-
glandin, serotonin, substance P and acetylcholine, which
stimulate nociceptors and induce hyperalgesia and allo-
dynia [16-18]. It has been demonstrated that the in-
crease in SF-36 score is slow in the 1st post-operative
month and then accelerates at six and 12 months, when
local inflammation and pain have been resolved [19,20].
Inflammation and pain at the joint after TKA can limit
rehabilitation and delay functional recovery [18].
Innovative therapeutic strategies are required to locally
control the inflammatory reaction following TKA.
It has been demonstrated that PEMFs have an agonist ef-
fect on A2A adenosine receptors, and this explains the anti-
inflammatory effects observed in experimental [8,9,21] and
clinical [10,11] studies. Knees in sheep undergoing
osteochondral grafts exposed to PEMFs show a reduced
concentration in the synovial fluid of pro-inflammatory
cytokines (IL-1β, tumor necrosis factor alpha: TNF-α) [22].
In vitro, PEMFs exposure prevents the release of PGE2 by
synoviocytes cultured in the presence of pro-inflammatory
cytokines (lipopolysaccharide, TNF-α) [23].
Figure 5 VAS Score. Mean values of VAS in the control group and I-ONE therapy group during the study. Vertical bars represent the standard
error. *p< 0.0001, °p< 0.001, }p< 0.05, p values refer to a comparison between groups at each follow-up visit using two tailed heteroschedastic
Student’s t-test. +p< 0.05, statistically significant difference versus pre-op.
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PEMFs to control the inflammatory reaction that follows
surgical procedures. Two randomized, prospective and
double-blind studies have been conducted in patients
undergoing arthroscopic procedure on the knee. The
first study included patients with cartilage lesions under-
going microfractures, while the second concerned
patients undergoing anterior cruciate ligament recon-
struction. In both studies, early functional recovery of
the joint and diminished consumption of NSAIDs were
reported [10,11].
In patients undergoing hip revision surgery, PEMFs
treatment resulted in early pain control and enhanced
functional recovery [15]. Straburzynska-Lupa et al., in a
clinical study of 25 patients treated with PEMFs com-
bined with local cryotherapy following TKA, describe
reduced pain, reabsorption of the edema and improved
functional recovery [24].
On the basis of the above evidence, this prospective,
randomized and controlled trial was conducted to verify
whether the treatment with I-ONE therapy, in addition
to standard rehabilitation, could control pain, reduce
swelling and improve functional recovery in patients
undergoing TKA.
The Knee Score, based on objective examination of
joint, was significantly better for the I-ONE group at
two and six months after TKA, indicating that the posi-
tive effect is maintained even after the end of the treat-
ment. Furthermore, the values of the Knee Score in the
control group at 12 months were comparable with those
observed in the experimental group two months post
TKA.
The Functional Score, which measures the subjective
evaluation of functional recovery, does not demonstrate
statistically significant differences between the treated
and control groups. These results are in agreement withthose reported by other authors concerning the lack of
correlation between the parameters of the subjective
evaluation scales and those of the clinical-functional
scales [11,25].
SF-36 Health Survey score demonstrates that patients
treated with I-ONE therapy after TKA had significantly
higher values than the control group until month twelve.
Furthermore, at 12 months the SF-36 value of the control
group equated with that of the I-ONE group at one month.
The values observed for the control group were com-
pared with information available in the literature for
Knee Score, Functional Score and SF-36 Health Survey.
Breugem et al. [26] reported a change in Knee Score of
30 points over 12 months, which compares favorably
with the 26 points change in this study. The major dif-
ference was observed for Functional Score, where the
changes were 24 points versus 34 in the present study.
In the control group, the SF-36 value doubled at 12
months follow-up and similar findings have been
reported by Brandes et al. [27]. In this study, the score
values in the control group were comparable to those in
other studies and the differences observed can be
ascribed to the populations investigated, and surgical
and rehabilitation procedures [28,29].
Pain, monitored on the VAS scale, at all follow-ups
was significantly lower in treated group with respect to
control one. Swelling was resolved earlier in the treated
group; no significant difference between groups was
observed at 6 and 12 months. Other authors have
reported that limitation due to swelling was important
during the acute period (one month after TKA) and the
improvement continued until 12 months after surgery
[14,30]. At one month after TKA, only 33% of patients
in the experimental group, versus 93% in the control
one, required NSAIDs (p = 0.0017). The above observa-
tions are in agreement with previous reports concerning
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At six months, the number of patients using NSAIDs
was still high (46%) in the control group (p< 0.05 vs ex-
perimental group); however, it further diminished and at
12 months there was no difference between groups. It is
accepted that recovery after TKA is longer than after
total hip prosthesis. Jones et al., using a large series of
patients (#256) undergoing TKA, reported pre-operatively
average pain score of 43, increasing to 75 six months after
surgery (100 indicating no pain); the study did not report
the use of NSAIDs [31]. Baker et al. reported that 19%
of patients still suffered persistent pain one year after
TKA [32].
The lack of a placebo group is a limitation of this study,
but it must be acknowledged that all clinical evaluations
were carried out by physicians unaware whether the patient
belonged to the control or experimental group. The small
population size did not allow to reliably apply the group x
time interaction effect test in the analysis of the results. Fur-
thermore, the limited number of patients may explain the
difference in Functional Scores observed at the baseline be-
tween the two groups. Patients’ compliance was a concern,
as the use of I-ONE for four hours per day for 60 days
requires significant commitment. However, the treatment
was well accepted, and patient compliance was high (3.9
hours per day average use) as the device is portable, battery
operated and can be worn while walking or at rest.
Conclusions
This study shows that I-ONE therapy can be started soon
after TKA. The treatment has been well tolerated and no
negative side effects have been reported. The lack of the
placebo group prevents to precisely quantify the contribu-
tion of the treatment to the observed pain relief and short-
ening of functional recovery. Nevertheless, I-ONE therapy
may represent an important adjunct to postoperative
treatment by preventing the detrimental effect of inflam-
mation elicited by TKA on joint tissues, with short and
long term positive benefits for patients.Competing interests
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